Novavax, Inc, a global company advancing protein-based vaccines using its Matrix-M™ adjuvant, will present results from the study during two communication sessions displayed at IDWeek 2023 , October 11-15, and three oral presentations at the World Vaccine Congress (WVC) Europe 2023 (WVC EU), from October 16 to 19. The strengths of the study. Highlights include clinical data on Novavax's BA.1, BA.5 and bivalent variants, evaluation of its prototype COVID-19 vaccine in children aged 6 to 11, real-world data on adverse reactions after COVID vaccination and an update on its COVID-19-Influenza Combination (CIC) vaccine candidate.
“We are excited to share the latest clinical data and real-world evidence that advances the science behind our protein-based vaccine technology,” said Dr. Filip Dubovsky, President of Research and Development at Novavax. “This data will help expand our label and describe characteristics that can help guide vaccine choice.” »
At IDWeek, Novavax will present data on key COVID-19 vaccine characteristics that drive vaccine choice, as well as clinical data from two studies comparing its Omicron BA.1 and BA.5 vaccines to the ability to its prototype COVID-19 vaccine induced superior neutralizing antibody responses against BA.1 and BA.5 viruses in people previously vaccinated with mRNA vaccines.
At WVC EU, Novavax will present data from its real-world study on the impact of vaccines on productivity, which focuses on the weight and impact of vaccine reactogenicity (undesirable local/systemic side effects solicited), its Hummingbird™ global phase 2b /3 clinical trial evaluating its prototype vaccine in children aged 6 to 11 years, as well as its CIC vaccine candidate.
About Novavax
Novavax, Inc. promotes improved health by discovering, developing and commercializing innovative vaccines that help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg , Maryland(United States), offers a differentiated vaccine platform that combines an approach based on recombinant proteins, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant, to improve the immune response. Focusing on the most pressing health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and combined COVID-19 and influenza
